Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rankning i aktier #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Aktiekurs
$0.00023723
Senast synkroniserad: 2024-08-26
Marknadsvärde
$1.41K
Förändring (1 dag)
111.67%
Förändring (1 år)
0.00%
Land
FR
Handel Pharnext S.A. (ALPHA)

Kategori

Utdelningsavkastning för Pharnext S.A. (ALPHA)
Utdelningsavkastningen (TTM) för Pharnext S.A. (aktiesymbol: ALPHA) per 2022-12-31 är: 0.00%
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Pharnext S.A. (ALPHA) från 2012 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter